Bell'
Conditions
Interventions
One group receives a high dose of PSL at 200 mg/day + Hespander + Mannitol intravenously.
Another group receives a normal dose of PSL at 60 mg/day orally + the antiviral agent + FCV 1500mg/day.
Sponsors
Department of Otolaryngology, Head and Neck Surgery, Yamagata University Faculty of Medicine
Tohoku University School of medicine Tohoku Medical and Pharmaceutical University Kurashiki central hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.within 7 days of the onset of the disease 2.an HB grade of V or VI 3.follow-up can be performed until complete recovery from facial paralysis or 12 months from onset of the disease 4.informed consent has been obtained
Exclusion criteria
Exclusion criteria: 1.recurrent palsy 2.auricular redness or strong otalgia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The patients are divided into two groups based on the treatment protocols with:Group 1 receiving a high dose of PSL at 200 mg/day + Hespander + Mannitol intravenously; Group 2 receiving a normal dose of PSL at 60 mg/day orally + the antiviral agent VACV at 3000 mg/day. We assess complete recovery as an HB grade of grade I at 1 year. | — |
Countries
Japan
Contacts
Public ContactTakatoshi Furukawa
Yamagata University Faculty of Medicine Department of Otolaryngology, Head and Neck Surgery
Outcome results
None listed